Cannabis Law Report

DECEMBER 26, 2021

December 17, 2021 ·. – December 16, 2021) – Entheon Biomedical Corp. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. US Provisional Patent Filed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

AUGUST 3, 2021

The Shares were offered in each of the provinces of Canada, excluding Québec, pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated July 5, 2021. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. Vigorous scientific research and clinical trials are needed.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. During the six months ended September 30, 2021, the Company raised approximately $4.1 million for the three months ended September 30, 2021, from approximately $1.48

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

DECEMBER 9, 2021

Phil Wolfson’s Ketamine Research Foundation, in support of their research into the awareness, understanding, and potential of psychedelics for the treatment of mental health disorders. Nue Life launched its proprietary nue.app on November 8 to increase access to psychedelic treatment as a catalyst for lasting change.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

JANUARY 12, 2022

. “Gb Sciences has established a pipeline of patent-protected combination therapies for the treatment of medical conditions affecting hundreds of millions of people,” said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. Media Contact. In addition, Gb Sciences has 12 U.S. Savannah Muir.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Yaden & Roland R. Mitchell et al., 11 × 11.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

DECEMBER 9, 2021

Thu, December 9, 2021, . 9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. Media Contact: media@mindmed.co.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is a limited liability corporation formed under the laws of Arizona , which operates 10 ketamine infusion treatment clinics, across Arizona , Colorado , Florida , Illinois , Minnesota , Nevada , Texas , and Washington. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

JULY 6, 2021

July 06, 2021 08:30 ET | Source: Ehave. MIAMI, July 06, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC A replay of the interview is available on the media section of the Company’s website at: [link]. Dr. Bankole Johnson was featured in a March 5 th 2021 Forbes article, “Dr. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

DECEMBER 9, 2021

The Financing is expected to close on December 10, 2021. The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch.

Clinical Trials 52

Clinical Trials Research and Development Treatment Therapy 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.) 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JANUARY 20, 2022

Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K. Email: alexander.speiser@eleusisltd.com.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

JULY 8, 2021

Enveric Enters into Clinical Stage Development of Lead Asset, EV101, in Israel with MOH Approval. “Our goal with this study is to enhance the existing treatment’s efficacy through adding CBD to create a new standard of care, potentially improving and extending glioblastoma patients’ quality of life.”

Treatment 98

Treatment Clinical Trials CBD Patients 98

Cannabis Law Report

OCTOBER 22, 2021

21, 2021 (GLOBE NEWSWIRE) — Small Pharma Inc. s MHRA Innovation Passport provides us with access to specialist advice throughout the drug development process and has the potential to enable a speedier, more efficient development process for SPL026, the lead candidate in our psychedelic-assisted therapy approach for the treatment of MDD.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Media coverage of the paper led to a new stigma and political pressure ended the Spain MDMA study. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. While this research is certainly worth celebrating, the reality behind the message can be easily misunderstood in this age of social media.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

Cannabis Law Report

DECEMBER 28, 2021

.–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I Mack, Chairman and CEO of Virpax. to conduct this study in Canada.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

SEPTEMBER 1, 2019

The Victorian and New South Wales Governments had both begun clinical trials of cannabis products for children with severe epilepsy and for palliative care, respectively. Minister for Industry and Skills David Pisoni published a media release to mark the occasion, entitled South Australia welcomes cannabis industry leaders.

Clinical Trials 53

Clinical Trials Research and Development Medicine Cultivation 53

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. This article analyses media representations of medicinal cannabis in Australian medical publications. Background.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JUNE 4, 2021

there has never been a better time for new treatment options. This list is focused on those who have had the largest impact for 2021. . Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Scientific accomplishments (developments, discoveries, etc.). Followers.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

OCTOBER 12, 2021

SAN DIEGO–(BUSINESS WIRE)– #CBD — Radicle Science , a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021. Notably, Peter H.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Veriheal

JANUARY 28, 2022

Despite Social Media Buzz, Researchers Say CBD COVID Cure Not Yet a Reality. Lost in the media frenzy, however, was the fact that this finding wasn’t an end-all-be-all. Rather, it was only an indication that CBD’s ability to fight COVID-19 warranted further research under more rigorous clinical trials.

Dispensary 98

Dispensary Clinical Trials CBD Legalization 98